Drug Details
General Information of the Drug (ID: DR8652) | ||||
---|---|---|---|---|
Name |
SG611-VSTM1
|
|||
Molecular Type |
Gene therapy
|
|||
Disease | Acute lymphoblastic leukemia [ICD-11: 2B33] | Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Daunorubicin | Streptomyces peucetius | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [1] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
In-vivo Model | For a xenograft model, 1*109 human K562 cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice. | |||||
Experimental
Result(s) |
An important role for VSTM1 in the pathogenesis of leukemia, and SG611-VSTM1 may be a promising agent for enhancing chemosensitivity in leukemia therapy. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Bacterial Enterobacter Beta-lactamase (Bact ampC) | Molecule Info | [2] |